ACS BrightEdge Poised to Help Improve 1.5 Million Lives By Investing in Cancer-Focused Therapies and Technologies
BOSTON, Aug. 16, 2023 /PRNewswire/ -- BrightEdge LLC, the American Cancer Society's (ACS) venture capital and impact investment arm, published its most recent annual report, featuring how its portfolio of 18 companies has the potential to improve the lives of more than 1.5 million cancer patients and their families. BrightEdge's estimate is based on its proprietary Cancer Impact Investing Framework™ (CIIF), which evaluates and measures the actual and potential impact of investments made in accordance with the ACS mission-driven priorities.
- Using CIIF, BrightEdge invested in four new companies in 2022: CellCentric, Paradigm, Vincere Health and Naveris.
- Across its 18 portfolio companies, BrightEdge has invested $28.9M to date from the donor-funded ACS Impact Venture Fund (AIVF).
- "BrightEdge works alongside ACS to not only accelerate patient-centric therapies and technologies but also provide alternative funding for our vision," said Dr. Karen E. Knudsen , CEO of the American Cancer Society.
- Like traditional venture capital, BrightEdge invests in for-profit, early-stage companies developing cancer-focused therapeutics, diagnostics, devices and technologies.